期刊
ANNALS OF NEUROLOGY
卷 92, 期 5, 页码 888-894出版社
WILEY
DOI: 10.1002/ana.26469
关键词
-
资金
- Michael J. Fox Foundation for Parkinson's Research (MJFF) [11849, MJFF-000858]
- Agencia de Gestio d'Ajuts Universitaris de Recerca (AGAUR) [FI-2021, FI-B-00378]
- Spanish Ministry of Science, Innovation and Universities (MICIU) [FPU18/00194]
- Maria de Maeztu grant [MDM-2017-0729]
- Spanish Ministry of Economy and Competitiveness (MINECO
- AEI/FEDER/EU) [SAF2017-88076, PID2020-119386R-100, SAF2017-88812-R, PID2020-119236RB-I00]
- Instituto de Salud Carlos III (ISCIII) [CP19/00048]
- European Union
- Agencia Estatal de Investigacion (AEI
- AEI/FEDER/UE) [SAF2015-73508-JIN]
- CERCA programme of Generalitat de Catalunya
- Spanish Ministry of Economy and Competitiveness (MINECO)
The purpose of this study was to investigate whether differential phosphorylation states of blood markers can identify patients with LRRK2 Parkinson's disease (PD). It was found that there were specific increases of P-Ser-473-AKT levels in all G2019S carriers, either L2PD or L2NMC, absent in iPD.
The purpose of this study was to investigate whether differential phosphorylation states of blood markers can identify patients with LRRK2 Parkinson's disease (PD). We assessed phospho(P)-Ser-935-LRRK2 and P-Ser-473-AKT levels in peripheral blood cells from patients with G2019S LRRK2-associated PD (L2PD, n = 31), G2019S LRRK2 non-manifesting carriers (L2NMC, n = 26), idiopathic PD (iPD, n = 25), and controls (n = 40, total n = 122). We found no differences at P-Ser-935-LRRK2 between groups but detected a specific increase of P-Ser-473-AKT levels in all G2019S carriers, either L2PD or L2NMC, absent in iPD. Although insensitive to LRRK2 inhibition, our study identifies P-Ser-473-AKT as an endogenous candidate biomarker for peripheral inflammation in G2019S carriers using accessible blood cells. ANN NEUROL 2022
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据